Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 1.48% as of July 3, 2025, with key stocks such as ZhiHua Cell (688520) rising by 19.99% and Changchun High-tech (000661) by 8.34% [1] - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Fuxin Qibai monoclonal antibody, which is the first IL-1 inhibitor approved in China for treating acute gouty arthritis [1] - The drug shows rapid efficacy within 6 hours, comparable pain relief to steroids within 72 hours, and a nearly 90% reduction in the risk of first recurrence within 6 months, indicating a promising new treatment option for gout patients [1] Group 2 - Since the beginning of the year, the innovative drug sector has gained significant market attention due to policies, overseas expansion, and performance, although a slight adjustment has occurred recently due to accumulated gains [2] - The upcoming negotiations for the new round of medical insurance directory and the announcement of commercial insurance innovative drug directories are expected to catalyze further developments in the innovative drug sector, which remains a key investment theme [2] - The rapid development of artificial intelligence technology is anticipated to greatly benefit the pharmaceutical industry, particularly in drug development, auxiliary diagnosis, and service applications [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 64.83% of the index [3]